GLPBio

Lapatinib

Catalog No.: GC13608Purity:>99.50%Synonyms: GW572016; GW2016
COASDSData Sheet
Lapatinib is an orally administered dual EGFR and HER2 tyrosine kinase inhibitor that has shown significant efficacy in the treatment of HER2-positive breast cancer. The IC₅₀ values of Lapatinib against purified EGFR and HER2 are 10.2nM and 9.8nM, respectively.

Products are for research use only. Not for human use. We do not sell to patients.

Lapatinib
Cas No.: 231277-92-2
10mM (in 1mL DMSO)In Stock
$42.00
1
50mgIn Stock
$34.00
1
100mgIn Stock
$52.00
1
7gIn Stock
$1,234.00
1
Tel: (909) 407-4943 / (909) 689-7124Email: sales@glpbio.com

Citations

2 publicationsPublications from researchers using this product

Description

Lapatinib is an orally administered dual EGFR and HER2 tyrosine kinase inhibitor that has shown significant efficacy in the treatment of HER2-positive breast cancer[1]. The IC₅₀ values of Lapatinib against purified EGFR and HER2 are 10.2nM and 9.8nM, respectively[2].

In vitro, Lapatinib (50000, 10000, 2000, 400, 80, 0nM; 96h) and poziotinib combined with paclitaxel synergizes to inhibit the proliferation of ABCB1-overexpressing ovarian cancer cells in vitro[2]. Lapatinib (5μM; 24h) attenuated TOCP-induced ErbB2 expression in RSC96 cells[3]. Lapatinib (25, 50, 100, and 200μM; 24h) inhibits the proliferation of synovial fibroblasts in patients with arthritis[4]. Lapatinib (0-10μM; 24 and 48h) decreases the ACTH production and proliferation of corticotroph tumor cells[5].

In vivo, Lapatinib (25mg/kg; 4 days; p.o.) alleviates Tri-o-cresyl phosphate (TOCP)-induced axonal damage in the spinal cord of mouse[3]. Lapatinib (30mg/kg; 15 days; p.o.) reduces synovial hyperplasia and pannus formation in rats with arthritis and prevents the development of cartilage and bone destruction[6].

References:
[1] Raja Sharin RNFS, Khan J, Ibahim MJ, et al. Role of ErbB1 in the Underlying Mechanism of Lapatinib-Induced Diarrhoea: A Review. Biomed Res Int. 2022 Jun 28;2022:4165808.
[2] Rusnak DW, Lackey K, Affleck K, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther. 2001 Dec;1(2):85-94.
[3] McCorkle JR, Gorski JW, Liu J, et al. Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer. PLoS One. 2021 Aug 4;16(8):e0254205.
[4] Xu HY, Sun YJ, Sun YY, et al. Lapatinib alleviates TOCP-induced axonal damage in the spinal cord of mouse. Neuropharmacology. 2021 May 15;189:108535.
[5] Kehribar DY, Emmungil H, Türkmen NB, et al. EGFR blocker lapatinib inhibits the synthesis of matrix metalloproteinases from synovial fibroblasts. Turk J Med Sci. 2022 Aug;52(4):1355-1361.
[6] Asari Y, Kageyama K, Sugiyama A, et al. Lapatinib decreases the ACTH production and proliferation of corticotroph tumor cells. Endocr J. 2019 Jun 28;66(6):515-522.
[7] Ozgen M, Koca SS, Karatas A, et al. Lapatinib ameliorates experimental arthritis in rats. Inflammation. 2015 Feb;38(1):252-9.

Protocol

Cell experiment [1]:

Cell lines

ovarian cancer cell lines TOV-21G and OVCAR-3

Preparation Method

Cells were seeded in white-walled 96-well microplates at a density of 3×10³ cells per well in 100μL growth media and incubated for 24h at 37°C, 5% CO₂ to allow cells to attach. Subsequently, the growth media was removed and replaced with fresh media containing serially diluted drugs of interest or blank media (for untreated controls), and incubated for 96h. We tested each drug alone and in combination with five serially diluted concentrations, and cell viability was measured using CellTiter-Glo 2.0. For each pair of drugs, every concentration was tested in combination in at least 3 independent experiments using a 6×6 matrix design. The percentage viability for each combination was calculated by dividing the drug-treated signals by the untreated signals and multiplying by 100. Paclitaxel (1000, 167, 28, 4.6, 0.77, 0nM) was tested in combination with Lapatinib (50000, 10000, 2000, 400, 80, 0nM) and poziotinib (12500, 4167, 1389, 463, 154, 0nM). Synergy for each drug combination was assessed using the synergyfinder package in R, with the percentage of viable cells relative to untreated control cells as the basis for evaluation.

Reaction Conditions

50000, 10000, 2000, 400, 80, 0nM; 96h

Applications

Lapatinib and poziotinib combined with paclitaxel synergizes to inhibit the proliferation of ABCB1-overexpressing ovarian cancer cells in vitro.
Animal experiment [2]:

Animal models

male Balb/c mice, 8 weeks old and 20-25g

Preparation Method

Seventy-six mice were divided into three groups: Tri-o-cresyl phosphate (TOCP) treatment (n=33); TOCP plus Lapatinib (LPT) treatment (n=33); vehicle treatment (n=10). Mice from TOCP-treated group were given a single dose of TOCP at 900mg/kg by gavage, while mice from TOCP plus Lapatinib-treated group were treated twice with Lapatinib dissolved in 10% sulfobutyl-β-cyclodextrin at a dose of 25mg/kg (p.o.), 4h before and 4 days after TOCP treatment. Mice from control group were given corresponding vehicles. Mice were examined daily for the signs of TOCP intoxication for 21 days.
On day 2, 7, 14, and 21 after treatments, 3, 6, 6, and 6 mice at the corresponding sampling time points were sacrificed by cervical decapitation. Six mice from control group were sacrificed on day 21. The spinal cord and sciatic nerves were quickly dissected and frozen in liquid nitrogen before storing at -80°C for future use. For immunofluorescent staining, other 4 mice from each treatment group on day 7, 14, and 21 and 4 mice from control group on day 21 were anesthetized by intraperitoneal injection of sodium pentobarbital (60mg/kg body weight). Then the mice were perfused through the ascending aorta with 0.9% NaCl at room temperature followed by ice-cold 0.1M phosphate buffer solution (PBS) (pH 7.4) containing 4% (w/v) paraformaldehyde using a peristaltic pump. The perfused spinal cord and sciatic nerve tissues were postfixed in 4% paraformaldehyde for overnight at 4°C, after which they were cryoprotected by storage in 0.1M PBS containing 30% sucrose at 4°C for 2 days.

Dosage form

25mg/kg; 4 days; p.o.

Applications

Lapatinib alleviates Tri-o-cresyl phosphate (TOCP)-induced axonal damage in the spinal cord of mouse.

References:
[1] McCorkle JR, Gorski JW, Liu J, et al. Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer. PLoS One. 2021 Aug 4;16(8):e0254205.
[2] Xu HY, Sun YJ, Sun YY, et al. Lapatinib alleviates TOCP-induced axonal damage in the spinal cord of mouse. Neuropharmacology. 2021 May 15;189:108535.

Product Documents

Purity:>99.50%Appearance:A solid
COASDSData Sheet

Chemical Properties

CAS No.
231277-92-2
Synonyms
GW572016; GW2016
Chemical Name
N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine
SMILES
CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl
Molecular Formula
C29H26ClFN4O4S
Molecular Weight
581.06
Solubility
≥ 29.05mg/mL in DMSO
Storage
Store at -20°C
General tips
Select a suitable solvent according to the product solubility data. Once prepared, aliquot the stock solution to avoid repeated freeze-thaw cycles.
Use stock solutions within 6 months when stored at -80°C or within 1 month when stored at -20°C.
To improve solubility, warm the tube to 37°C and sonicate it for an appropriate period.
Shipping Condition
Evaluation samples are shipped with blue ice. Other available sizes are shipped at room temperature or with blue ice upon request.

CalculatorsMolarity / Dilution / Molecular Weight / Unit Conversion / In Vivo Formulation / Solubility

g/mol

Reviews

Review for Lapatinib

Rating: 5
  • 5 Star100%
  • 4 Star0%
  • 3 Star0%
  • 2 Star0%
  • 1 Star0%